PT-141 10mg

Researchers investigate peptide-receptor interaction using PT-141 in experimental settings. Peptide-receptor interaction examines how peptides bind to molecular targets on cells. Laboratory teams explore experimental signaling pathway models in controlled environments. Signaling pathway models are frameworks for studying molecular communication sequences. Scientists conduct controlled laboratory peptide studies under various experimental conditions. Research groups examine how receptor-targeting peptides function in cellular systems. These studies occur exclusively in research environments without clinical applications.

PT-141 is investigated in research environments for peptide signaling analysis. Scientists have studied this compound within controlled laboratory models using standardized protocols. The formulation is explored for experimental peptide signaling research in academic facilities. Researchers evaluate the peptide under controlled conditions without outcome claims.

Store PT-141 in cool, dry, light-protected conditions between 2-8°C. Light-protected conditions mean storage away from direct sunlight and intense artificial lighting. This product is intended for laboratory handling only by qualified research personnel. Qualified personnel have received appropriate training in peptide handling and storage procedures. Avoid moisture exposure as water content can affect peptide stability and quality. Avoid heat exposure above recommended temperature ranges to maintain structural integrity. Structural integrity refers to peptides maintaining their proper molecular configuration. Reconstituted solutions should follow established laboratory guidelines specific to peptide research protocols.

Each PT-141 batch undergoes comprehensive purity verification procedures through analytical testing. Analytical testing uses scientific instruments to measure peptide composition and quality. Our processes ensure batch-to-batch consistency across all research supply orders. Internal quality assurance standards follow research-grade supply positioning for peptide compounds. Research-grade supply means products meet specifications required for scientific laboratory use. Testing protocols verify peptide purity and structural characteristics using validated methods. Every unit meets our specifications before receiving distribution approval. Laboratory certificates accompany each order for institutional tracking and compliance documentation.

• CAS: 189691-06-3
• Chemical Formula: C₅₀H₆₈N₁₄O₁₀
• Molecular Weight: 1025.182 g/mol
• Peptide Sequence: Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)
• Synonyms: PT141
• Shelf life: 24 months from the manufacturing date.

PT-141 is a synthetic peptide consisting of seven amino acids in sequence. This heptapeptide is designed to interact with specific molecular receptor systems. Heptapeptide means a peptide containing exactly seven amino acid units. Receptor signaling means the process by which peptides trigger cellular responses. Cellular responses occur when receptors bind to peptides and initiate molecular changes. Signaling peptides are studied in research to understand molecular communication mechanisms. Molecular communication describes how cells exchange information through chemical messengers. Researchers investigate how synthetic peptides interact with melanocortin receptor systems. Melanocortin receptors are protein structures studied in experimental research models. Laboratory research examines peptide binding patterns, selectivity, and structural characteristics.

PT-141 provides a synthetic research peptide formulation developed for scientific applications. Synthetic peptides are manufactured compounds created through chemical synthesis processes. Each batch undergoes high-purity testing to ensure compound consistency across orders. The formulation is designed for controlled laboratory environments conducting receptor research. Receptor research examines how peptides interact with specific protein structures on cells. Secure packaging with discreet shipment protects the peptide during transit to research facilities.

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH). It is a non-selective agonist at melanocortin receptors, with documented activity at MC1R, MC3R, and MC4R in research models. Unlike earlier melanocortin compounds, PT-141 lacks the oxidation-labile methionine residue, contributing to improved chemical stability. Research uses PT-141 as a pharmacological tool for investigating melanocortin receptor pharmacology across subtypes.

Melanocortin receptors (MC1R–MC5R) are all Gs-coupled GPCRs that activate adenylyl cyclase, raising intracellular cAMP and activating PKA. In research models, MC4R activation in hypothalamic cell systems has been studied for effects on feeding behaviour regulatory circuits, autonomic nervous system output, and cardiovascular signalling. MC1R activation in melanocyte cell lines is characterised by increased melanogenesis. Comparative activation profiles across receptor subtypes are determined using cAMP accumulation assays in individually transfected cell systems.

Selectivity profiling of PT-141 across the five melanocortin receptor subtypes (MC1R–MC5R) uses cAMP accumulation assays in cell lines transiently or stably expressing each receptor, with native α-MSH and receptor-selective reference agonists as comparators. PT-141 shows significant activity at MC1R, MC3R, and MC4R. Its relatively low selectivity for individual subtypes makes it a useful pan-MC agonist tool compound for research requiring activation of multiple melanocortin receptor types simultaneously.

PT-141 is a cyclic lactam peptide; identity confirmation must verify both the linear sequence and the cyclisation between the side chains of Asp3 and Lys7. Mass spectrometry should confirm the expected molecular weight (~1025 Da for the free acid form). The cyclic structure should be distinguished from the linear form by MS/MS fragmentation analysis. HPLC purity documentation confirms absence of linear precursor and other synthesis impurities.

PT-141 (Bremelanotide) has received regulatory approval for specific clinical indications in certain jurisdictions. However, PT-141 as supplied by Elivena is a research-grade compound for use in controlled laboratory settings only, and is not supplied for personal therapeutic administration outside of formally regulated clinical contexts.